Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $20.00.

A number of equities analysts have commented on the stock. Wedbush downgraded shares of Alto Neuroscience from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Stifel Nicolaus dropped their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Finally, RODMAN&RENSHAW lowered shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd.

Alto Neuroscience Trading Up 2.0 %

Shares of NYSE ANRO traded up $0.09 during trading on Monday, hitting $4.61. The company had a trading volume of 327,572 shares, compared to its average volume of 374,663. The stock has a fifty day simple moving average of $9.69 and a two-hundred day simple moving average of $11.27. Alto Neuroscience has a fifty-two week low of $3.61 and a fifty-two week high of $24.00. The company has a quick ratio of 19.85, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. Analysts predict that Alto Neuroscience will post -2.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. acquired a new position in shares of Alto Neuroscience during the first quarter valued at $8,233,000. Price T Rowe Associates Inc. MD acquired a new stake in Alto Neuroscience in the first quarter worth about $9,788,000. Bowie Capital Management LLC acquired a new stake in Alto Neuroscience in the second quarter worth about $462,000. TD Asset Management Inc acquired a new stake in Alto Neuroscience in the second quarter worth about $928,000. Finally, Zimmer Partners LP acquired a new stake in Alto Neuroscience in the first quarter worth about $1,151,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.